LGD 3303 is a research compound being investigated for its potential to bind onto the androgenic receptors in muscles and bones, which may result in increased muscle and bone strength. Studies have found LGD-3303 to be a powerful and highly selective androgen receptor full agonist in skeletal muscle, sparing non-target tissues. This provides a novel and potentially safer treatment for osteoporosis.